Compare IPWR & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPWR | PDSB |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | United States | United States |
| Employees | 17 | 10 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.4M | 62.0M |
| IPO Year | 2013 | 2015 |
| Metric | IPWR | PDSB |
|---|---|---|
| Price | $3.98 | $0.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $10.75 | $9.00 |
| AVG Volume (30 Days) | 184.8K | ★ 313.5K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $2,603.56 | N/A |
| Revenue Next Year | $1,800.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.62 | $0.51 |
| 52 Week High | $9.30 | $1.55 |
| Indicator | IPWR | PDSB |
|---|---|---|
| Relative Strength Index (RSI) | 33.12 | 32.28 |
| Support Level | $2.80 | $0.62 |
| Resistance Level | $4.44 | $0.73 |
| Average True Range (ATR) | 0.32 | 0.05 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 8.89 | 9.30 |
Ideal Power Inc is engaged in the development of its broadly patented bidirectional power switches, creating efficient and ecofriendly energy control solutions for electric vehicles, electric vehicle charging, renewable energy, energy storage, UPS / data center, solid-state circuit breaker and other industrial and military applications. The company is focused on its patented Bidirectional, Bipolar Junction Transistor (B-TRAN) semiconductor technology. B-TRAN is a double-sided bidirectional AC switchable to deliver substantial performance improvements over conventional power semiconductors. The primary raw material used in the fabrication of B-TRAN devices is silicon wafers.
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells. The company has determined that it operates as a single reportable segment, developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy.